[1]温捷颖,欧阳淦权,李伟光,等.颞叶孤立性胶质母细胞瘤的手术治疗分析[J].中国临床神经外科杂志,2022,27(08):659-661666.[doi:10.13798/j.issn.1009-153X.2022.08.011]
　WEN Jie-ying,OUYANG Gan-quan,LI Wei-guang,et al.Surgical outcomes of patients with isolated temporal glioblastoma[J].,2022,27(08):659-661666.[doi:10.13798/j.issn.1009-153X.2022.08.011]
点击复制

颞叶孤立性胶质母细胞瘤的手术治疗分析()
分享到：

《中国临床神经外科杂志》[ISSN:1009-153X/CN:42-1603/TN]

卷:
27
期数:
2022年08期
页码:
659-661666
栏目:
论著
出版日期:
2022-08-31

文章信息/Info

Title:
Surgical outcomes of patients with isolated temporal glioblastoma
文章编号:
1009-153X(2022)08-0659-03
作者:
温捷颖; 欧阳淦权; 李伟光; 黄广龙
510515 广州，南方医科大学南方医院神经外科（温捷颖、欧阳淦权、李伟光、黄广龙）
Author(s):
WEN Jie-ying;  OUYANG Gan-quan;  LI Wei-guang;  HUANG Guang-long
Department of Neurosurgery, Nanfang Hospital of Southern Medical University, Gaungzhou 510515, China
关键词:
胶质母细胞瘤; 颞叶孤立性肿瘤; 显微手术; 前颞叶切除术; 疗效
Keywords:
Isolated temporal glioblastoma;  Anterior temporal lobectomy;  Survival prognosis
分类号:
R739.41;R651.1+1
DOI:
10.13798/j.issn.1009-153X.2022.08.011
文献标志码:
A
摘要:
目的 探讨颞叶孤立性胶质母细胞瘤的手术方法及疗效。方法 回顾性分析2016年7月至2020年5月手术治疗的38例颞叶孤立性胶质母细胞瘤的临床资料。接受肿瘤全切除+前颞叶切除术（ALT）治疗14例（ALT组），行常规颞叶肿瘤全切除术治疗24例（常规组）。术后随访6~28个月，中位数15个月；术后3、12个月采用KPS评分评估神经功能状态，其中KPS评分≥70分为预后良好；根据RANO标准评估肿瘤进展，国际抗癫痫联盟分级1级定义为癫痫完全控制；记录总生存期（OS）和无进展生存期（PFS）。结果 ALT组术后脑室开放率（100%，14/14）明显高于常规组（33.3%，8/24；P<0.001）。ALT组与常规组术后1年癫痫完全控制率（64.3% vs. 66.7%）、术后肿瘤进展率（78.5% vs. 70.8%）、术后3个月预后良好率（92.9% vs. 66.7%）均无统计学差异（P>0.05）。ALT组术后1年预后良好率（78.6%，11/14）明显高于常规组（41.7%，10/24；P<0.05）。ALT组中位PFS和中位OS较常规组均明显延长（P<0.05）。多因素Cox比例回归风险模型分析显示，ALT是延长PFS（OR=7.3；95% CI 1.105~47.422；P=0.037）和OS（OR=7.8；95% CI 1.117~55.183；P=0.041）的独立预测因子。结论 对于颞叶孤立性胶质母细胞瘤，在全切除肿瘤基础上，进行ALT，可明显改善病人预后。
Abstract:
Objective To investigate the methods and outcomes of microsurgery for the patients with isolated temporal glioblastoma. Methods The clinical of 38 patients with isolated temporal glioblastoma who underwent micorsurgery from July 2016 to May 2020 were analyzed retrospectively. Fourteen patients were treated with total tumor resection and anterior temporal lobectomy (ALT group) and 24 patients were treated with conventional total resection of temporal lobe tumors (conventional group). Postoperative follow-up ranged from 6 months to 28 months, with a median of 15 months. The KPS score was used to assess the neurological status 3 and 12 months after surgery, and the KPS score ≥70 points was classified as good prognosis. Tumor progression was assessed according to the RANO criteria, and the International League Against Epilepsy Classification Level 1 was defined as complete control of epilepsy. Overall survival (OS) and progression-free survival (PFS) were recorded. Results The postoperative ventricle opening rate of ALT group (100%, 14/14) was significantly higher than conventional group (33.3%, 8/24; P<0.001). There was no significant differences in the complete control rate of epilepsy 1 year after surgery (64.3% vs. 66.7%, 16/24), the postoperative tumor progression rate (78.5% vs. 70.8%) and the good prognosis rate 3 months after operation (92.9% vs. 66.7%) between ALT and conventional groups (P>0.05). The good prognosis rate of ALT group (78.6%, 11/14) was significantly higher than that (41.7%, 10/24) of the conventional group 1 year after operation (P<0.05). The median PFS and median OS of ALT group were significantly longer than those of conventional group (P<0.05). Multivariate Cox proportional regression hazard model analysis showed that ALT was an independent predictor for longer PFS (OR=7.3; 95% CI 1.105~47.422; P=0.037) and OS (OR=7.8; 95% CI 1.117~55.183; P=0.041). Conclusions ALT can significantly improve the prognosis of patients with isolated temporal glioblastoma on the basis of total tumor resection.

参考文献/References:

[1]Ma R, Taphoorn MJB, Plaha P. Advances in the management of glioblastoma [J]. J Neurol Neurosurg Psychiatry, 2021, 92(10): 1103-1111.
[2]张　超，易　勇. 不同手术方式对颞叶低级别胶质瘤相关癫痫的研究[J]. 中国微侵袭神经外科杂志，2021，26（6）：262-265.
[3]马思远，樊　星，乔　慧. 额颞叶脑胶质瘤病人术前脑电图特征的量化分析研究[J]. 中国微侵袭神经外科杂志，2020，25（9）：397-400.
[4]Shah AH, Mahavadi A, Di L, et al. Survival benefit of lobectomy for glioblastoma: moving towards radical supramaximal resection [J]. J Neurooncol, 2020, 148(3): 501-508.
[5]Pessina F, Navarria P, Cozzi L, et al. Maximize surgical resection beyond contrast-enhancing boundaries in newly diagnosed glioblastoma multiforme: is it useful and safe: a single institution retrospective experience [J]. J Neurooncol, 2017, 135(1): 129-139.
[6]季　晶，张军霞，颜　伟，等. 额颞枕叶非功能区胶质瘤的手术策略[J]. 中华神经外科杂志，2016，32（5）：467-472.
[7]Borger V, Hamed M, Ilic I, et al. Seizure outcome in temporal glioblastoma surgery: lobectomy as a supratotal resection regime outclasses conventional gross-total resection [J]. J Neurooncol, 2021, 152(2): 339-346.
[8]Zigiotto L, Annicchiarico L, Corsini F, et al. Effects of supra-total resection in neurocognitive and oncological outcome of high-grade gliomas comparing asleep and awake surgery [J]. J Neurooncol, 2020, 148(1): 97-108.
[9]Li YM, Suki D, Hess K, et al. The influence of maximum safe resection of glioblastoma on survival in 1229 patients: can we do better than gross-total resection [J]. J Neurosurg, 2016, 124(4): 977-988.
[10]Chaichana KL, Parker SL, Olivi A, et al. Long-term seizure outcomes in adult patients undergoing primary resection of malignant brain astrocytomas [J]. J Neurosurg, 2009, 111(2): 282-292.
[11]Yordanova YN, Moritz-Gasser S, Duffau H. Awake surgery for WHO Grade Ⅱ gliomas within "noneloquent" areas in the left dominant hemisphere: toward a "supratotal" resection [J]. J Neurosurg, 2011, 115(2): 232-239.
[12]Yang K, Ellenbogen Y, Martyniuk A, et al. Reoperation in adult patients with recurrent glioblastoma: a matched cohort analysis [J]. Neurooncol Adv, 2022, 4(1): vdac115.

相似文献/References:

[1]谢宝树　张　林　王　宇　贾　锋　殷玉华.复发性多发胶质母细胞瘤的预后分析[J].中国临床神经外科杂志,2016,(06):333.[doi:10.13798/j.issn.1009-153X.2016.06.005]
　XIE Bao-shu,ZHANG Lin,WANG Yu,et al.Analysis of prognoses in patients with recurrent multiple glioblastomas[J].,2016,(08):333.[doi:10.13798/j.issn.1009-153X.2016.06.005]
[2]宋贵东 综述　高之宪 审校.贝伐单抗治疗复发胶质母细胞瘤的研究进展[J].中国临床神经外科杂志,2015,(10):638.[doi:10.13798/j.issn.1009-153X.2015.10.022]
[3]李继强　杨吉安　邵灵敏　吴庭枫　刘宝辉　陈谦学.稳定低表达BAG3的胶质母细胞瘤U87细胞株的构建及鉴定[J].中国临床神经外科杂志,2015,(06):353.[doi:10.13798/j.issn.1009-153X.2015.06.011]
　LI Ji-qiang,YANG Ji-an,SHAO Ling-min,et al.Construction and identification of U87 glioblastoma cell strain with a stable low expression of BAG3[J].,2015,(08):353.[doi:10.13798/j.issn.1009-153X.2015.06.011]
[4]桂志勇　冯　军　黄俊红　白敬洋.靶向沉默c-fos基因表达对胶质瘤U87MG细胞增殖与侵袭的影响[J].中国临床神经外科杂志,2017,(12):834.[doi:10.13798/j.issn.1009-153X.2017.12.011]
　GUI Zhi-yong,FENG Jun,HUANG Jun-hong,et al.Effects of c-fos targeted silence on proliferation and invasiveness of human glioma cell U87[J].,2017,(08):834.[doi:10.13798/j.issn.1009-153X.2017.12.011]
[5]王娇燕　孟凡华　刘魏然　魏春晓　林丽萍.SWI在胶质母细胞瘤与单发脑转移瘤鉴别中的价值[J].中国临床神经外科杂志,2018,(01):13.[doi:10.13798/j.issn.1009-153X.2018.01.005]
　WANG Jiao-yan,MENG Fan-hua,LIU Wei-ran,et al.Value of susceptibility-weighted imaging in differentiative diagnosis of glioblastomas and solitary brain metastases[J].,2018,(08):13.[doi:10.13798/j.issn.1009-153X.2018.01.005]
[6]张治元　王汉东　樊友武　贾　玥　吴晋蓉.胶质肉瘤15例分析及文献复习[J].中国临床神经外科杂志,2018,(02):69.
　ZHANG Zhi-yuan,WANG Han-dong,FAN You-wu,et al.Diagnosis and treatment of gliosarcoma: a report of 15 cases and literature review[J].,2018,(08):69.
[7]郑锐哲　姜秀峰　陈二涛　孙兆良　冯东福.胶质母细胞瘤卒中术后继发硬膜下水瘤1例[J].中国临床神经外科杂志,2019,(02):128.[doi:10.13798/j.issn.1009-153X.2019.02.022]
[8]胡 玥,薛小燕,李子超,等.阿苯达唑抑制胶质瘤裸鼠模型肿瘤生长[J].中国临床神经外科杂志,2019,(06):348.[doi:10.13798/j.issn.1009-153X.2019.06.010]
　HU Yue,XUE Xiao-yan,LI Zi-chao,et al.Albendazole inhibits tumor growth in nude mice model of glioma[J].,2019,(08):348.[doi:10.13798/j.issn.1009-153X.2019.06.010]
[9]殷安安　陆　南　贺亚龙　章　翔　刘玉河.TRIM38基因非CpG岛DNA甲基化与胶质母细胞瘤临床预后的关系[J].中国临床神经外科杂志,2020,(02):76.[doi:10.13798/j.issn.1009-153X.2020.02.005]
　YIN An-an,LU Nan,HE Ya-long,et al.Impacts of TRIM38 non-CpG island DNA methylation alterations on clinical prognosis in patients with glioblastomas[J].,2020,(08):76.[doi:10.13798/j.issn.1009-153X.2020.02.005]
[10]吴　蛟　易　勇　赵卓琳　周良学　周世军.贝伐珠单抗联合化疗治疗胶质母细胞瘤的meta分析[J].中国临床神经外科杂志,2020,(02):82.[doi:10.13798/j.issn.1009-153X.2020.02.007]
　WU Jiao,YI Yong,ZHAO Zhuo-lin,et al.Efficacy and safety of bevacizumab combined with chemotherapy for glioblastoma: a meta-analysis[J].,2020,(08):82.[doi:10.13798/j.issn.1009-153X.2020.02.007]

备注/Memo

备注/Memo:
（2022-05-21收稿，2022-06-28修回）
通讯作者：黄广龙，E-mail：hgl1020@163.com
更新日期/Last Update: 2022-09-30